X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA DISHMAN PHARMA PLETHICO PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x -1.1 25.1 - View Chart
P/BV x 0.0 3.3 0.5% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 PLETHICO PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
DISHMAN PHARMA
Mar-16
PLETHICO PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs395374 105.5%   
Low Rs31129 24.3%   
Sales per share (Unadj.) Rs604.4197.8 305.6%  
Earnings per share (Unadj.) Rs32.521.2 153.2%  
Cash flow per share (Unadj.) Rs51.334.7 147.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs473.6179.9 263.2%  
Shares outstanding (eoy) m34.0880.69 42.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.41.3 27.7%   
Avg P/E ratio x6.611.9 55.3%  
P/CF ratio (eoy) x4.27.2 57.3%  
Price / Book Value ratio x0.51.4 32.2%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m7,26220,306 35.8%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m1,5965,355 29.8%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m20,59815,961 129.1%  
Other income Rs m386265 145.6%   
Total revenues Rs m20,98416,226 129.3%   
Gross profit Rs m2,8184,103 68.7%  
Depreciation Rs m6421,091 58.9%   
Interest Rs m1,593944 168.7%   
Profit before tax Rs m9692,334 41.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138624 -22.2%   
Profit after tax Rs m1,1071,711 64.7%  
Gross profit margin %13.725.7 53.2%  
Effective tax rate %-14.326.7 -53.5%   
Net profit margin %5.410.7 50.1%  
BALANCE SHEET DATA
Current assets Rs m18,87711,018 171.3%   
Current liabilities Rs m11,8969,517 125.0%   
Net working cap to sales %33.99.4 360.4%  
Current ratio x1.61.2 137.1%  
Inventory Days Days36110 32.5%  
Debtors Days Days19835 567.9%  
Net fixed assets Rs m9,86116,304 60.5%   
Share capital Rs m341161 211.1%   
"Free" reserves Rs m12,33112,907 95.5%   
Net worth Rs m16,13914,516 111.2%   
Long term debt Rs m4,7064,189 112.3%   
Total assets Rs m33,14629,805 111.2%  
Interest coverage x1.63.5 46.3%   
Debt to equity ratio x0.30.3 101.0%  
Sales to assets ratio x0.60.5 116.0%   
Return on assets %8.18.9 91.4%  
Return on equity %6.911.8 58.2%  
Return on capital %12.317.5 70.1%  
Exports to sales %21.424.8 86.2%   
Imports to sales %15.23.7 407.5%   
Exports (fob) Rs m4,4023,956 111.3%   
Imports (cif) Rs m3,136596 525.9%   
Fx inflow Rs m4,4024,952 88.9%   
Fx outflow Rs m3,184697 456.9%   
Net fx Rs m1,2194,255 28.6%   
CASH FLOW
From Operations Rs m2,4372,786 87.5%  
From Investments Rs m-6,265-1,529 409.8%  
From Financial Activity Rs m2,490-941 -264.6%  
Net Cashflow Rs m-1,337316 -422.6%  

Share Holding

Indian Promoters % 82.7 61.4 134.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 3.7 116.2%  
FIIs % 5.5 12.7 43.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 22.1 33.9%  
Shareholders   10,665 46,261 23.1%  
Pledged promoter(s) holding % 85.7 35.8 239.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare PLETHICO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS